Galectin Therapeutics Inc.
GALT
Price:
$2.84
Market Cap:
$176.87M
Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. The company's lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, a galactoarabino-rhamnogalacturonan polysaccharide polymer that is in Phase III clinical trial for the treatment of liver fibrosis associated with fatty liver disease and non-alcoholic steatohepatitis cirrhosis, as well as for the treatment of cancer. It also engages in developing GM-CT-01, which is in pre-clinical development stage for the treatment of cardiac and vascular fibrosis, as well as focuses on developing belapectin for the treatment ...[Read more]
Industry
Biotechnology
IPO Date
2002-09-04
Stock Exchange
NASDAQ
Ticker
GALT
The ROE as of September 2024 (TTM) for Galectin Therapeutics Inc. (GALT) is 67.01%
According to Galectin Therapeutics Inc.’s latest financial reports and current stock price. The company's current ROE is 67.01%. This represents a change of 292.36% compared to the average of 17.08% of the last 4 quarters.
Galectin Therapeutics Inc. (GALT) Historical ROE (quarterly & annually)
How has GALT ROE performed in the past?
The mean historical ROE of Galectin Therapeutics Inc. over the last ten years is -528.89%. The current 67.01% ROE has changed -112.67% with respect to the historical average. Over the past ten years (40 quarters), GALT's ROE was at its highest in in the March 2022 quarter at 160.33%. The ROE was at its lowest in in the December 2021 quarter at -276.03%.
Average
-528.89%
Median
-79.70%
Minimum
-3468.65%
Maximum
115.58%
Galectin Therapeutics Inc. (GALT) ROE by Quarter and Year
Discovering the peaks and valleys of Galectin Therapeutics Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 4.27%
Maximum Annual ROE = 115.58%
Minimum Annual Increase = -103.33%
Minimum Annual ROE = -3468.65%
| Year | ROE | Change |
|---|---|---|
| 2023 | 68.17% | -41.02% |
| 2022 | 115.58% | -103.33% |
| 2021 | -3468.65% | 4.27% |
| 2020 | -79.45% | 170.71% |
| 2019 | -29.35% | -85.44% |
| 2018 | -201.51% | -85.19% |
| 2017 | -1360.85% | 662.77% |
| 2016 | -178.41% | 123.14% |
| 2015 | -79.95% | 7.34% |
| 2014 | -74.49% | -49.30% |
Galectin Therapeutics Inc. (GALT) Average ROE
How has GALT ROE performed in the past?
The current ROE of Galectin Therapeutics Inc. (GALT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-1094.97%
5-year avg
-678.74%
10-year avg
-528.89%
Galectin Therapeutics Inc. (GALT) ROE vs. Peers
How is GALT’s ROE compared to its peers?
Galectin Therapeutics Inc.’s ROE is greater than Madrigal Pharmaceuticals, Inc. (-95.61%), greater than Viking Therapeutics, Inc. (-15.05%), less than Sarepta Therapeutics, Inc. (5.17%), greater than Hepion Pharmaceuticals, Inc. (-328.66%), less than PTC Therapeutics, Inc. (57.03%), greater than Intercept Pharmaceuticals, Inc. (-78.24%), greater than Terns Pharmaceuticals, Inc. (-39.58%), greater than Akero Therapeutics, Inc. (-29.56%), less than Reata Pharmaceuticals, Inc. (19.32%), greater than DiaMedica Therapeutics Inc. (-38.56%), greater than Milestone Pharmaceuticals Inc. (-165.26%), less than Seres Therapeutics, Inc. (313.56%), greater than Inhibikase Therapeutics, Inc. (-194.17%), greater than Oncolytics Biotech Inc. (-114.55%), greater than 89bio, Inc. (-35.42%), greater than Pliant Therapeutics, Inc. (-41.05%), greater than Arcellx, Inc. (-12.42%), greater than Stoke Therapeutics, Inc. (-57.89%),
| Company | ROE | Market cap |
|---|---|---|
| -95.61% | $5.26B | |
| -15.05% | $7.55B | |
| 5.17% | $12.12B | |
| -328.66% | $3.93M | |
| 57.03% | $2.78B | |
| -78.24% | $794.69M | |
| -39.58% | $706.53M | |
| -29.56% | $1.94B | |
| 19.32% | $6.57B | |
| -38.56% | $172.70M | |
| -165.26% | $82.57M | |
| 313.56% | $160.00M | |
| -194.17% | $8.66M | |
| -114.55% | $73.14M | |
| -35.42% | $877.99M | |
| -41.05% | $767.31M | |
| -12.42% | $4.59B | |
| -57.89% | $797.09M |
Build a custom stock screener for Galectin Therapeutics Inc. (GALT) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Galectin Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Galectin Therapeutics Inc. (GALT) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Galectin Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Galectin Therapeutics Inc.'s ROE?
How is the ROE calculated for Galectin Therapeutics Inc. (GALT)?
What is the highest ROE for Galectin Therapeutics Inc. (GALT)?
What is the 3-year average ROE for Galectin Therapeutics Inc. (GALT)?
What is the 5-year average ROE for Galectin Therapeutics Inc. (GALT)?
How does the current ROE for Galectin Therapeutics Inc. (GALT) compare to its historical average?